Response to Dr Lamy and Dr Gonzalez-Rodriguez

Affiliations

¹ San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA, USA.
² Geneva University Hospital, Geneva, Switzerland.
³ Laval University and CHU de Québec-Université Laval (CHUL), Quebec City, Canada.
⁴ Amgen Inc., Thousand Oaks, CA, USA.

Free article

Comment

Steven R Cummings et al. J Bone Miner Res. 2018 Mar.

Free article

. 2018 Mar;33(3):548.

doi: 10.1002/jbmr.3403.

¹ San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA, USA.
² Geneva University Hospital, Geneva, Switzerland.
³ Laval University and CHU de Québec-Université Laval (CHUL), Quebec City, Canada.
⁴ Amgen Inc., Thousand Oaks, CA, USA.

No abstract available

Comment on

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.
Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP. Cummings SR, et al. J Bone Miner Res. 2018 Feb;33(2):190-198. doi: 10.1002/jbmr.3337. Epub 2017 Nov 22. J Bone Miner Res. 2018. PMID: 29105841 Clinical Trial.
Underestimation of Vertebral Fractures After Denosumab Discontinuation.
Lamy O, Gonzalez-Rodriguez E. Lamy O, et al. J Bone Miner Res. 2018 Mar;33(3):547. doi: 10.1002/jbmr.3370. Epub 2018 Feb 15. J Bone Miner Res. 2018. PMID: 29393984 No abstract available.